Key Highlights
- 19.61% is the pre-market decline indicated for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) on November 19, 2026, to USD 17.95 from a calculated prior close of USD 22.33 on 542,861 shares.
- 41% is the reduction in the risk of death reported in the Phase 3 REGAL trial of galinpepimut-S, with a hazard ratio of 0.59, a p-value of 0.035 and median survival of 24 months versus 14.7 months.
- 150.0 million is the USD size of the public offering SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) launched on November 17, 2026, with a 30-day option for underwriters to buy up to USD 22.5 million more.
- 134.7 million is the USD cash balance at September 30, 2026, against a third quarter net loss of USD 10.1 million and a calculated market Capitalization near USD 3.65 billion.
What Moved SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) in Pre-Market Trading on November 19, 2026 (-USD 4.38, -19.61%)
The indicated pre-market price of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) on November 19, 2026 is USD 17.95, a pre-market move of -19.61% on a pre-market Volume of 542,861 shares. On a calculated basis, the prior close was USD 22.33 (USD 17.95 divided by 0.8039) and the USD move is -USD 4.38. Market capitalization is calculated at about USD 3.65 billion, using 203,527,833 shares outstanding at September 30, 2026 times the indicated price.
The Rationale: Capital Raise After a Positive Phase 3 Readout for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)
On November 17, 2026 the company announced that the pivotal Phase 3 REGAL trial of galinpepimut-S, known as GPS, met its primary endpoint of overall survival in 126 patients with acute myeloid leukemia. The hazard ratio was 0.59, a 41% reduction in the risk of death, with a p-value of 0.035. Median survival was 24 months versus 14.7 months for best available therapy. The company plans to meet the FDA and expects to file a Biologics License Application in the first half of 2027. The same day it launched a proposed USD 150.0 million underwritten public offering of common stock, with J.P. Morgan and TD Cowen as joint book-running managers. No pricing terms were identified in published coverage. As general context, a new share issue after a rally often pressures a stock through dilution.
Valuation, Liquidity and Risks for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)
The latest reported period is the third quarter ended September 30, 2026. Research and Development expense was USD 7.0 million versus USD 4.2 million a year earlier. Net loss was USD 10.1 million, or USD 0.05 per share, against USD 6.8 million, and the nine month net loss was USD 28.1 million. Cash was USD 134.7 million, up from USD 71.8 million at December 31, 2025, while shares outstanding rose from 153,103,459 to 203,527,833. With no product revenue, the calculated market capitalization is roughly 27 times cash. Dilution, regulatory timing and reliance on a single lead candidate are the main risks.
Where Things Stand
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is indicated at USD 17.95 pre-market on November 19, 2026, down 19.61% from a calculated prior close of USD 22.33, on 542,861 shares. The setting is a Phase 3 REGAL result with a hazard ratio of 0.59, followed by a proposed USD 150.0 million offering whose final size and terms were not assured. Cash of USD 134.7 million at September 30, 2026, a nine month net loss of USD 28.1 million and a calculated market capitalization near USD 3.65 billion frame the balance sheet. This article is informational and is not Investment advice.






Please wait processing your request...